In prostate cancer, this is through increasing the expression of integrin subunits (ITGAV and ITGB1) specific to prostate cancer bone metastasis,96 by preventing the expression of prostate‐derived Ets factor (PDEF) which inhibits metastasis,90 through blocking the transport of zinc ions which in turn increases NF‐κB‐mediated signalling by reducing inhibitor of NF‐κB alpha (IκBα) activity,92 and by promoting expression of the epithelial to mesenchymal transition (EMT)‐inducing Slug transcription factor.105. Here, ITGAV is linked to prostate carcinoma.